Kidney Cancer (Renal Cell)

12 protocols meet the specified criteria


A Phase 1 Study of Pembrolizumab (MK-3475) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors


Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors (SGNTV-001)


Clinically-Efficient Strategies to Address Tobacco Smoke Exposure in Pediatric Practice


PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]


NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations


NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations


Precision Cancer Survivorship Cohort


Increasing patient portal adoption among Black cancer patients: Designing messaging and identifying proper communication channels


Cancer Knowledge, Quality of Life, Health Behaviors, and Views About Health Care and Medical Research among Adult Cancer Survivors and Adults At-Risk for Cancer: A Study by the UF Health Cancer Center s Community-Partnered Cancer Disparities Research Collaborative


Population Health Assessment in the UFHCC Catchment Area Random Digit Dialing Survey: Cancer Screening Knowledge and Health Habits in the UFHCC Catchment Area


A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response


Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas